ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
ENB Therapeutics Announces Poster Presentation at the 2022 Summit for Cancer Immunotherapy
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint
Comments are closed.